Lialda®: Delayed-Release Therapy for Ulcerative Colitis
What Is Lialda®?
Lialda® is a brand-name, delayed-release formulation of mesalamine (5-aminosalicylic acid), prescribed to treat mild to moderate ulcerative colitis. It belongs to a class of medications known as aminosalicylates, which work by reducing inflammation in the lining of the colon. Designed with a multi-matrix system (MMX), Lialda® releases mesalamine gradually throughout the colon to achieve prolonged anti-inflammatory action.
This once-daily tablet is ideal for patients seeking fewer pills while maintaining reliable, targeted therapy for gastrointestinal (GI) flare-ups and remission maintenance.
How Lialda® Supports Gastrointestinal Health
Ulcerative colitis is a chronic inflammatory bowel disease (IBD) that causes symptoms such as abdominal pain, urgency, and bloody diarrhea. Lialda® delivers localized treatment to the colon, helping to minimize inflammation, manage flares, and maintain remission without broad systemic effects. The delayed-release mechanism ensures the medication reaches the distal bowel—precisely where inflammation tends to be most active.
For patients who struggle with adherence due to multiple daily doses, Lialda® offers simplicity and improved compliance, with many clinical trials confirming its efficacy and tolerability.
“With once-daily dosing and targeted delivery, Lialda® empowers patients to manage ulcerative colitis with greater ease.”
Why King’s Pharmacy Cares About GI Therapy
At King’s Pharmacy and Compounding Center, we understand that managing GI disorders requires more than just medication—it demands a personalized approach. While Lialda® is a commercial product, we work closely with GI specialists to ensure patients get consistent access to it, along with compounding support for related therapies like topical hydrocortisone, suppositories, or enemas when needed.
We also assist with patient education, medication synchronization, and navigating insurance hurdles for high-cost medications like Lialda®.
FAQs About Lialda®
Lialda® contains mesalamine, but it uses a unique MMX delivery system that releases the drug slowly throughout the colon, enhancing its effectiveness for ulcerative colitis.
No. Lialda® is a proprietary delayed-release product and cannot be compounded. However, King’s Pharmacy can compound mesalamine-based therapies in other forms if your provider recommends it.
Many patients begin to notice symptom improvement within 2–4 weeks, though full effects may take longer depending on the severity of inflammation.
Yes. Other mesalamine formulations or different delivery routes may be explored with your gastroenterologist. We can also support transitions to topical or compounded GI therapies as needed.
